Coherent Market Insights

Clinical Mass Spectrometry Market to Surpass US$ 1,206.9 Million by 2027

Clinical Mass Spectrometry Market to Surpass US$ 1,206.9 Million by 2027 - Coherent Market Insights

Publish In: Dec 24, 2019

Global Clinical Mass Spectrometry Market, by Product Type (Gas chromatography–mass spectrometry (GC-MS) instrument, Liquid chromatography–mass spectrometry (LC-MS) instrument, MALDI-TOF mass spectrometer, Capillary electrophoresis–mass spectrometry, and Ion mobility spectrometry-mass spectrometry), by Application (Clinical Testing, Proteomics, and Drug discovery), by End User (Research Laboratories, Diagnostic Laboratories, and Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$  697.2  million in 2019, and is expected to exhibit a CAGR of 5.5% over the forecast period (2019 - 2027). Increasing investments in R&D activities by pharmaceutical companies are driving growth of the global clinical mass spectrometry market. Mass spectrometry continues to play a prominent role in laboratory medicine. For instance, in 2019, Biotage AB collaborated with Shandong Yingsheng Biotechnology Co., Ltd to focus on research, production and selling in vitro diagnostic reagents and medical equipment, building a genetic detection platform and mass spectrometry detection platform around metabolomics and genetics.

As a part of the collaboration, Biotage and Yingsheng agreed to develop clinical mass spectrometry applications in China, where Biotage will provide systems and consumables through its analytical chemistry portfolio and Yingsheng will sell it with its brand name. Moreover, use of clinical mass spectrometry in laboratory developed tests (LDTs) is driving growth of this market. Properties such as sensitive analytical capabilities and enhancements continue to bring the technology to the edge of new scientific discovery and research applications. Matrix-assisted laser desorption/ionization - time of flight (MALDI-TOF) have wide application in microbiology laboratories. MALDI-TOF systems that have been designated as medical devices that support FDA-cleared or CE-marked assays. Assays that have received FDA clearance or CE-marking over the last few years have largely revolved around microbiological identifications with MALDI-TOF. These assays are different from the majority of the clinical mass spectrometry market, which is covered by laboratory developed tests (LDTs).

Browse 43 Market Data Tables and 33 Figures spread through 169 Pages and in-depth TOC on "Global Clinical Mass Spectrometry Market, by Product Type (Gas chromatography–mass spectrometry (GC-MS) instrument , Liquid chromatography–mass spectrometry (LC- MS) instrument, MALDI-TOF mass spectrometer, Capillary electrophoresis–mass spectrometry, and Ion mobility spectrometry-mass spectrometry), by Application (Clinical Testing, Proteomics, and Drug discovery), by End User (Research Laboratories, Diagnostic Laboratories, and Hospitals), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) Global Forecast to 2027"

To know the latest trends and insights related to clinical mass spectrometry market, click the link below:

https://www.coherentmarketinsights.com/market-insight/clinical-mass-spectrometry-market-193

Key Takeaways of the Clinical Mass Spectrometry Market:

  • The global clinical mass spectrometry market is expected to exhibit a CAGR of 5.5% over the forecast period (2019 – 2027), owing to technological advancements in mass spectrometry and increasing adoption in laboratory developed tests.
  • Among region, Asia Pacific is expected to witness significant growth in the global clinical mass spectrometry market over the forecast period, owing to high R&D investment by pharmaceutical companies.
  • Gas chromatography – mass spectrometry (GC-MS) instrument segment held a dominant position in clinical mass spectrometry market, owing to high adoption of this technology by players operating in the market.
  • Major players operating in the global clinical mass spectrometry market include Bruker Corporation, Kore Technology Limited, Bergman Messgerate Entwicklung KG, Mass Spectrometry Instruments (MSI), Thermo Fisher Scientific Inc., Agilent Technologies, and Danaher Corporations.

 

Need a Custom Report?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports


Want to Buy a Report but have a Limited Budget?

We help clients to procure the report or sections of the report at their budgeted price. Kindly click on the below to avail


Logo

Reliability and Reputation

ESOMAR
DUNS Registered
Clutch
DMCA Protected

9001:2015

Reliability and Reputation

27001:2022

Reliability and Reputation

EXISTING CLIENTELE

Created billion dollars of revenue impact on thousands of clients

trusted clients logo
© 2024 Coherent Market Insights Pvt Ltd. All Rights Reserved.